vs
BioAge Labs, Inc.（BIOA）与Rigetti Computing, Inc.（RGTI）财务数据对比。点击上方公司名可切换其他公司
BioAge Labs, Inc.的季度营收约是Rigetti Computing, Inc.的1.6倍（$3.1M vs $1.9M），BioAge Labs, Inc.净利率更高（-842.9% vs -974.7%，领先131.8%），Rigetti Computing, Inc.自由现金流更多（$-19.5M vs $-28.4M）
Altos Labs是一家美国生物技术研究企业，主营业务为开发可延缓或逆转人类衰老进程的寿命延长疗法，围绕该方向开发基于诱导多能干细胞的专用细胞疗法。该公司由俄罗斯裔科技企业家尤里·米尔纳，以及杰夫·贝佐斯等投资人于2021年出资成立，2022年正式启动运营。
Rigetti Computing总部位于美国加利福尼亚州伯克利，是专业的超导量子集成电路研发商，产品主要应用于量子计算机领域。公司还推出了名为Forest的云平台，支持开发者编写各类量子算法。
BIOA vs RGTI — 直观对比
营收规模更大
BIOA
是对方的1.6倍
$1.9M
净利率更高
BIOA
高出131.8%
-974.7%
自由现金流更多
RGTI
多$8.9M
$-28.4M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.1M | $1.9M |
| 净利润 | $-25.9M | $-18.2M |
| 毛利率 | — | 34.9% |
| 营业利润率 | -923.4% | -1209.7% |
| 净利率 | -842.9% | -974.7% |
| 营收同比 | — | -17.9% |
| 净利润同比 | — | 88.1% |
| 每股收益（稀释后） | $-0.72 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIOARGTI
| Q4 25 | $3.1M | $1.9M | ||
| Q3 25 | $2.1M | $1.9M | ||
| Q2 25 | $2.4M | $1.8M | ||
| Q1 25 | $1.5M | $1.5M | ||
| Q4 24 | — | $2.3M | ||
| Q3 24 | $0 | $2.4M | ||
| Q2 24 | — | $3.1M | ||
| Q1 24 | — | $3.1M |
净利润BIOARGTI
| Q4 25 | $-25.9M | $-18.2M | ||
| Q3 25 | $-20.2M | $-201.0M | ||
| Q2 25 | $-21.6M | $-39.7M | ||
| Q1 25 | $-12.9M | $42.6M | ||
| Q4 24 | — | $-153.0M | ||
| Q3 24 | $-23.4M | $-14.8M | ||
| Q2 24 | — | $-12.4M | ||
| Q1 24 | — | $-20.8M |
毛利率BIOARGTI
| Q4 25 | — | 34.9% | ||
| Q3 25 | — | 20.7% | ||
| Q2 25 | — | 31.4% | ||
| Q1 25 | — | 30.0% | ||
| Q4 24 | — | 44.1% | ||
| Q3 24 | — | 50.6% | ||
| Q2 24 | — | 64.5% | ||
| Q1 24 | — | 49.1% |
营业利润率BIOARGTI
| Q4 25 | -923.4% | -1209.7% | ||
| Q3 25 | -1126.6% | -1055.4% | ||
| Q2 25 | -1027.0% | -1103.9% | ||
| Q1 25 | -1133.4% | -1469.6% | ||
| Q4 24 | — | -813.3% | ||
| Q3 24 | — | -729.4% | ||
| Q2 24 | — | -521.2% | ||
| Q1 24 | — | -543.4% |
净利率BIOARGTI
| Q4 25 | -842.9% | -974.7% | ||
| Q3 25 | -982.0% | -10321.9% | ||
| Q2 25 | -894.0% | -2201.8% | ||
| Q1 25 | -891.0% | 2895.3% | ||
| Q4 24 | — | -6726.5% | ||
| Q3 24 | — | -623.8% | ||
| Q2 24 | — | -402.5% | ||
| Q1 24 | — | -680.6% |
每股收益（稀释后）BIOARGTI
| Q4 25 | $-0.72 | $-0.08 | ||
| Q3 25 | $-0.56 | $-0.62 | ||
| Q2 25 | $-0.60 | $-0.13 | ||
| Q1 25 | $-0.36 | $0.13 | ||
| Q4 24 | — | $-0.80 | ||
| Q3 24 | $-6.70 | $-0.08 | ||
| Q2 24 | — | $-0.07 | ||
| Q1 24 | — | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $281.1M | $44.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $272.1M | $546.2M |
| 总资产 | $294.9M | $666.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BIOARGTI
| Q4 25 | $281.1M | $44.9M | ||
| Q3 25 | $285.8M | $26.1M | ||
| Q2 25 | $297.3M | $57.2M | ||
| Q1 25 | $320.5M | $37.2M | ||
| Q4 24 | — | $67.7M | ||
| Q3 24 | $334.5M | $20.3M | ||
| Q2 24 | — | $20.7M | ||
| Q1 24 | — | $35.1M |
总债务BIOARGTI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $7.1M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $9.9M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BIOARGTI
| Q4 25 | $272.1M | $546.2M | ||
| Q3 25 | $277.5M | $371.8M | ||
| Q2 25 | $294.8M | $553.3M | ||
| Q1 25 | $313.2M | $207.1M | ||
| Q4 24 | — | $126.6M | ||
| Q3 24 | $313.7M | $122.8M | ||
| Q2 24 | — | $122.2M | ||
| Q1 24 | — | $115.6M |
总资产BIOARGTI
| Q4 25 | $294.9M | $666.6M | ||
| Q3 25 | $305.1M | $630.3M | ||
| Q2 25 | $322.1M | $636.7M | ||
| Q1 25 | $343.8M | $269.1M | ||
| Q4 24 | — | $284.8M | ||
| Q3 24 | $337.4M | $157.3M | ||
| Q2 24 | — | $162.4M | ||
| Q1 24 | — | $162.1M |
负债/权益比BIOARGTI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.02× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.03× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-28.3M | $-14.9M |
| 自由现金流经营现金流 - 资本支出 | $-28.4M | $-19.5M |
| 自由现金流率自由现金流/营收 | -921.5% | -1042.5% |
| 资本支出强度资本支出/营收 | 3.6% | 244.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-82.3M | $-77.2M |
8季度趋势，按日历期对齐
经营现金流BIOARGTI
| Q4 25 | $-28.3M | $-14.9M | ||
| Q3 25 | $-16.0M | $-13.8M | ||
| Q2 25 | $-20.0M | $-16.2M | ||
| Q1 25 | $-17.4M | $-13.7M | ||
| Q4 24 | — | $-8.5M | ||
| Q3 24 | — | $-15.4M | ||
| Q2 24 | — | $-13.5M | ||
| Q1 24 | — | $-13.1M |
自由现金流BIOARGTI
| Q4 25 | $-28.4M | $-19.5M | ||
| Q3 25 | $-16.1M | $-19.7M | ||
| Q2 25 | $-20.1M | $-21.8M | ||
| Q1 25 | $-17.8M | $-16.2M | ||
| Q4 24 | — | $-9.8M | ||
| Q3 24 | — | $-17.7M | ||
| Q2 24 | — | $-15.6M | ||
| Q1 24 | — | $-18.6M |
自由现金流率BIOARGTI
| Q4 25 | -921.5% | -1042.5% | ||
| Q3 25 | -782.2% | -1012.4% | ||
| Q2 25 | -834.5% | -1212.4% | ||
| Q1 25 | -1226.0% | -1100.4% | ||
| Q4 24 | — | -432.1% | ||
| Q3 24 | — | -744.5% | ||
| Q2 24 | — | -504.3% | ||
| Q1 24 | — | -610.5% |
资本支出强度BIOARGTI
| Q4 25 | 3.6% | 244.8% | ||
| Q3 25 | 1.1% | 302.5% | ||
| Q2 25 | 6.6% | 314.7% | ||
| Q1 25 | 29.4% | 173.0% | ||
| Q4 24 | — | 56.4% | ||
| Q3 24 | — | 95.8% | ||
| Q2 24 | — | 66.3% | ||
| Q1 24 | — | 180.0% |
现金转化率BIOARGTI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.32× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIOA
暂无分部数据
RGTI
| Collaborative Research And Other Professional Services | $1.7M | 93% |
| Other | $131.0K | 7% |
